FSD Pharma Inc. Announces Closing of Private Placement
FSD Pharma Inc. Announces Closing of Private Placement
TORONTO, ON / ACCESSWIRE / December 5, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (the "Company" or "FSD"), is pleased to announce that, further to its news release on November 27, 2023, it has closed a non-brokered private placement and issued 24 class A multiple voting shares ("Class A Shares") of the Company at a price of $1.90 per Class A Share for gross proceeds of $45.60 (the "Offering").
安大略省多伦多/ACCESSWIRE/2023年12月5日/富世达制药公司(纳斯达克股票代码:HUGE)(CSE:HUGE)(FRA: 0K9A)(“公司” 或 “FSD”)欣然宣布,继2023年11月27日发布新闻稿后,该公司已完成非经纪私募并发行了24股A类多表决权股票(“A类股票”)每股A类股票的价格为1.90美元,总收益为45.60美元(“发行”)。
All securities issued pursuant to the Offering are subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws of Canada. The Company intends to use the proceeds of the Offering for general working capital purposes.
根据加拿大适用的证券法,根据本次发行发行的所有证券的法定持有期为四个月外加发行之日起一天。公司打算将本次发行的收益用于一般营运资金用途。
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
本新闻稿不应构成出售要约或招揽买入要约,也不得在任何将此类要约、招标或出售为非法的州出售证券。所发行的证券过去和将来都没有根据经修订的1933年《美国证券法》进行注册,如果没有注册或不受经修订的1933年《美国证券法》和适用的州证券法的注册要求的适用豁免,则不得在美国发行或出售。
MI 61-101 Disclosure
密歇根州 61-101 披露
Xorax Family Trust ("Xorax"), a trust of which Zeeshan Saeed, the Chief Executive Officer and Co-Chairman of FSD Pharma is a beneficiary, and Fortius Research and Trading Corp. ("Fortius"), a corporation of which Anthony Durkacz, a director of FSD is a director, purchased all the Class A Shares issued pursuant to the Offering. The participation by such insiders is considered a "related-party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in respectively, sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the Offering as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61- 101).
Xorax Family Trust(“Xorax”)(FSD Pharma首席执行官兼联席董事长Zeeshan Saeed是该信托的受益人)和Fortius Research and Trading Corp.(“Fortius”)(Fsd董事安东尼·杜尔卡奇担任其董事的公司)购买了根据本次发行的所有A类股票。此类内部人士的参与被视为《多边文书》61-101所指的 “关联方交易” -在特殊交易中保护少数证券持有人 (“MI 61-101”)。对于关联方参与本次发行,公司依据分别载于MI 61-101的第5.5 (a) 和5.7 (1) (a) 节中MI 61-101的正式估值和小股东批准要求的豁免,既不是交易标的的的的公允市场价值(根据MI 61-101确定),也不是交易对价的公允市场价值,因为该交易涉及关联方,超过公司市值的25%(根据MI 61-101确定)。
The Company did not file a material change report more than 21 days before the expected closing of the Offering because the details of the participation therein by related parties to the Company were not settled until shortly prior to the closing, and the Company wished to close on an expedited basis for business reasons.
由于公司关联方参与本次发行的细节直到收盘前不久才确定,而且出于业务原因,公司希望加快完成本次发行的重大变更报告,因此该公司希望加快完成本次发行。
Early Warning Disclosure
预警披露
This press release is being issued in accordance with the requirements of National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with the filing of the Early Warning Reports by Xorax, whose registered address is 3688 Stratton Woods Court, Mississauga, Ontario, L5L 4V2, and Fortius, whose registered address is 2045 Lakeshore Boulevard West, Suite 3006, Toronto, Ontario M6V 2Z6 (collectively, the "Acquirors") in respect of the Offering of the Company, whose registered address is 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
本新闻稿是根据国家仪器62-103的要求发布的- 预警系统及相关的收购投标和内幕举报问题 (“NI 62-103”),涉及Xorax(注册地址为安大略省密西沙加斯特拉顿伍兹法院3688号,L5L 4V2)和注册地址为安大略省多伦多湖岸大道西2045号3006套房 M6V 2Z6(统称 “收购方”)提交的预警报告该公司的注册地址为加拿大安大略省多伦多湾街199号4000套房 M5L 1A9。
On December 4, 2023, Xorax acquired 12 Class A Shares at a price of $1.90 per share for a total price of $22.80 and Fortius acquired 12 Class A Shares at a price of $1.90 per share for a total price of $22.80 pursuant to the Offering
2023年12月4日,Xorax根据本次发行,以每股1.90美元的价格收购了12股A类股票,总价为22.80美元,Fortius以每股1.90美元的价格收购了12股A类股票,总价为22.80美元
Following the Offering, Xorax owns 36 Class A Shares and 441,031 class B subordinate voting shares ("Class B Shares") representing 50% of the outstanding Class A Shares, 1.12% of the outstanding Class B Shares, and 17.54% of the voting rights attached to all of the Company's outstanding voting securities. Prior to the Offering, Xorax owned 24 Class A Shares and 441,031 Class B Shares, which represented 50% of the outstanding Class A Shares, 1.12% of the outstanding Class B Shares, and 13.45% of the voting rights attached to all of the Company's outstanding voting securities.
发行后,Xorax拥有36股A类股票和441,031股B类次级有表决权股票(“B类股票”),占已发行A类股票的50%,占已发行B类股票的1.12%,以及公司所有已发行有表决权证券的17.54%。在发行之前,Xorax拥有24股A类股票和441,031股B类股票,占已发行A类股票的50%,占已发行B类股票的1.12%,以及公司所有已发行有表决权证券的13.45%。
Following the Offering, Fortius owns 36 Class A Shares and 106,043 Class B Shares, representing 50% of the outstanding Class A Shares, 0.27% of the outstanding Class B Shares, and 16.98% of the voting rights attached to all of the Company's outstanding voting securities. Prior to the Offering, Fortius owned 24 Class A Shares and 106,043 Class B Shares, which represented 50% of the outstanding Class A Shares, 0.27% of the outstanding Class B Shares, and 12.81% of the voting rights attached to all of the Company's outstanding voting securities.
发行后,Fortius拥有36股A类股票和106,043股B类股票,占已发行A类股票的50%,占已发行B类股票的0.27%,以及公司所有已发行有表决权证券的16.98%。发行前,Fortius拥有24股A类股票和106,043股B类股票,占已发行A类股票的50%,占已发行B类股票的0.27%,占公司所有已发行有表决权证券的12.81%。
The Acquirors acquired the above-noted Class A Shares for investment purposes. In the future, the Acquirors will evaluate their respective investment in the Company from time to time and may, based on such evaluation, market conditions and other circumstances, increase or decrease its shareholdings as circumstances require through market transactions, private agreements, or otherwise.
收购方出于投资目的收购了上述A类股票。将来,收购方将不时评估各自在公司的投资,并可能根据此类评估、市场状况和其他情况,通过市场交易、私人协议或其他方式视情况增加或减少其持股量。
The Acquirors currently have no plans or intentions which would result in a corporate transaction, a sale or transfer of a material amount of the assets of the Company or any of its subsidiaries, a change in the board of directors or management of the Company, including any plans or intentions to change the number or term of directors or to fill any existing vacancies on the board, a material change in the Company's business or corporate structure, a change in the Company's charter, bylaws or similar instruments or another action which might impede the acquisition of control of Company by any person or company, a class of securities of the Company being delisted from, or ceasing to be authorized to be quoted on, a marketplace, the Company ceasing to be a reporting issuer in any jurisdiction of Canada, a solicitation of proxies from securityholders, or an action similar to any of those enumerated.
收购人目前没有任何计划或意图导致公司交易、出售或转让公司或其任何子公司的大量资产、公司董事会或管理层的变动,包括任何更改董事人数或任期或填补董事会现有空缺的计划或意图,公司业务或公司结构发生重大变化,公司章程变更,章程或类似文书或其他可能阻碍收购的行动任何人或公司对公司的控制权,公司的一类证券被从市场上除牌或停止获准在市场上市,公司不再是加拿大任何司法管辖区的报告发行人,向证券持有人征集代理人,或采取与所列举的任何行为相似的行动。
Copies of the Early Warning Reports being filed by the Acquirors may be obtained on the Company's SEDAR+ profile or by emailing rehansk@gmail.com or calling 416-786-6063 for Xorax's Early Warning Report, or by emailing anthony@firstrepubliccapital.com or calling 416-720-4360 Fortius' Early Warning.
收购方提交的预警报告的副本可在公司的SEDAR+个人资料上获取,也可以发送电子邮件至 rehansk@gmail.com 或致电416-786-6063获取Xorax的预警报告,或者发送电子邮件至 anthony@firstrepubliccapital.com 或致电416-720-4360 Fortius的预警报告。
Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
CSE及其监管服务提供商(该术语在CSE的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
About FSD
关于 FSD
FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD has also licensed UNBUZZD, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nu and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. FSD continues its R&D activities to develop novel formulations for alcohol misuse disorders and continues the development of such treatments for use in the healthcare sector. FSD maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.
FSD是一家生物制药公司,致力于建立创新资产和生物技术解决方案组合,用于治疗具有挑战性的神经退行性和代谢性疾病以及酒精滥用障碍,候选药物处于不同开发阶段。FSD通过其全资子公司Lucid Psycheceuticals Inc.(“Lucid”)专注于其主要化合物Lucid-MS(前身为Lucid-21-302)(“Lucid-MS”)的研究和开发。Lucid-MS 是一种获得专利的新化学实体,在临床前模型中被证明可以防止和逆转髓鞘降解,这是多发性硬化的潜在机制。FSD还向Celly Nu许可了UNBUZZD,这是一种有助于肝脏和大脑功能的天然成分、维生素和矿物质的专有配方,用于消费娱乐领域,可以快速缓解个人饮酒的影响,并有权就Celly Nu通过销售使用许可协议授予的技术权利生产的产品所产生的收入收取特许权使用费。FSD 继续开展研发活动,开发治疗酒精滥用障碍的新配方,并继续开发用于医疗保健领域的此类治疗方法。FSD通过其全资子公司FSD Strategic Investments Inc. 维持战略投资组合,这些贷款由住宅或商业地产担保。
Cautionary Note Regarding Forward-Looking Statements
关于前瞻性陈述的警示说明
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the news release, such forward-looking statements include, but are not limited to, statements regarding, the Company's performance, business objectives and milestones and the anticipated timing thereof; the anticipated use of net proceeds from the Offering; the Acquirors evaluations with respect to their future investment in the Company; and the Acquirors plans with respect to future transactions or material changes.
本新闻稿中列出的某些信息可能包含前瞻性陈述,这些陈述涉及大量已知和未知的风险和不确定性,其中某些风险和不确定性超出了公司的控制范围。前瞻性陈述通常以 “计划”、“继续”、“预期”、“项目”、“打算”、“相信”、“预期”、“估计”、“可能”、“将”、“可能”、“潜在”、“提议” 和其他类似词语为特征,或关于某些事件或条件 “可能” 或 “将” 发生的陈述 或者被实现和其他类似的表达方式。前瞻性陈述基于陈述发表之日管理层的估计和意见。在新闻稿中,此类前瞻性陈述包括但不限于有关公司业绩、业务目标和里程碑及其预期时机的陈述;本次发行净收益的预期用途;收购方对公司未来投资的评估;以及收购方对未来交易或重大变更的计划。
In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation: the Company's ability to comply with all applicable regulations and laws, including environmental, health and safety laws; the Company having sufficient working capital for future operating activities; the ability of the Company to achieve its business objectives and milestones and the anticipated timing of execution; the Company's ability to continue as a going concern and the Company's ability to use the proceeds from the Offering for the business objectives outlined herein.
在本新闻稿中做出前瞻性陈述时,公司应用了几项实质性假设,包括但不限于:公司遵守所有适用法规和法律的能力,包括环境、健康和安全法;公司有足够的营运资金用于未来的运营活动;公司实现其业务目标和里程碑的能力以及预期的执行时间;公司继续经营的能力以及公司使用所得收益的能力此处概述的业务目标的产品。
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: changes in general economic, business and political conditions, including changes in the financial markets; consents or authorizations required; changes in laws, regulations and policies affecting the Company's operations; currency fluctuations; environmental issues and liabilities; the potential impact of the announcement or consummation of the Offering on relationship, including with regulatory bodies, employees, suppliers, customers and competitors; the inability of the Company to obtain additional financing for continued operations on terms acceptable to the Company; the lack of control over the Company's investees; risks relating to investing in the Class A Shares and Class B Shares; risks relating to the use of proceeds from the Offering; volatility in the market price of the Class A Shares and Class B Shares; dilution of shareholders' holdings; negative operating cash flow; the negative effects of interest rate and exchange rate changes; the potential impact of health crises and market instability due to the COVID-19 pandemic; risks relating to the Company s reliance on key employees; limitations in the liquidity of the Class A Shares; litigation risks; the Company's inability to expand into new business areas and geographic markets; management of growth; and the Company's inability to continue as a going concern.
上述前瞻性陈述和假设列表并不详尽。由于前瞻性陈述涉及未来的事件和状况,因此就其本质而言,它们涉及固有的风险和不确定性。由于多种因素和风险,实际结果可能与此类前瞻性陈述目前的预期或暗示的结果存在重大差异。其中包括:总体经济、商业和政治条件的变化,包括金融市场的变化;需要获得同意或授权;影响公司运营的法律、法规和政策的变化;货币波动;环境问题和责任;本次发行的宣布或完成对关系,包括与监管机构、员工、供应商、客户和竞争对手的关系的潜在影响;公司无法按条款为持续运营获得额外融资公司可以接受;缺乏对公司被投资者的控制权;与投资 A 类股票和 B 类股票相关的风险;与使用本次发行收益相关的风险;A 类股票和 B 类股票的市场价格波动;股东持有的稀释;运营现金流为负;利率和汇率变动的负面影响;COVID-19 疫情导致的健康危机和市场不稳定的潜在影响;与公司依赖关键员工有关的风险;限制A类股票的流动性;诉讼风险;公司无法向新的业务领域和地域市场扩张;增长管理;以及公司无法继续经营业务。
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
如果这些风险或不确定性中的一项或多项成为现实,或者前瞻性陈述所依据的假设被证明不正确,则实际结果可能与本文描述的预期、计划、预期、相信、估计或预期的结果存在重大差异。尽管公司试图确定可能导致实际业绩存在重大差异的重要风险、不确定性和因素,但可能还有其他因素导致业绩与预期、估计或预期不符。除非适用法律另有要求,否则公司无意更新这些前瞻性信息,也不承担任何义务。
Contacts:
联系人:
FSD Pharma Inc.
FSD Pharma Inc.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, FSD Pharma Inc.
Email: Zsaeed@fsdpharma.com
Telephone: (416) 854-8884
Zeeshan Saeed,FSD Pharma Inc. 创始人、首席执行官兼董事会执行联席主席
电子邮件:Zsaeed@fsdpharma.com
电话:(416) 854-8884
Investor Relations
投资者关系
Email: ir@fsdpharma.com, info@fsdpharma.com
Website:
电子邮件:ir@fsdpharma.com,info@fsdpharma.com
网站:
ClearThink
ClearTh
Email: nyc@clearthink.capital
Telephone: (917) 658-7878
电子邮件:nyc@clearthink.capital
电话:(917) 658-7878
SOURCE: FSD Pharma Inc.
来源:FSD Pharma Inc.